177 related articles for article (PubMed ID: 20697116)
1. Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival.
Sala E; Kataoka M; Pandit-Taskar N; Ishill N; Mironov S; Moskowitz CS; Mironov O; Collins MA; Chi DS; Larson S; Hricak H
Radiology; 2010 Oct; 257(1):125-34. PubMed ID: 20697116
[TBL] [Abstract][Full Text] [Related]
2. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
3. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
Kim CK; Park BK; Choi JY; Kim BG; Han H
J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
5. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
Bristow RE; Giuntoli RL; Pannu HK; Schulick RD; Fishman EK; Wahl RL
Gynecol Oncol; 2005 Nov; 99(2):294-300. PubMed ID: 16051330
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Pathologic Grade and Prognosis in Mucoepidermoid Carcinoma of the Lung Using ¹⁸F-FDG PET/CT.
Park B; Kim HK; Choi YS; Kim J; Zo JI; Choi JY; Shim YM
Korean J Radiol; 2015; 16(4):929-35. PubMed ID: 26175595
[TBL] [Abstract][Full Text] [Related]
7. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
8. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
9. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
10. 13N-Ammonia PET/CT for detection of recurrent glioma: a prospective comparison with contrast-enhanced MRI.
Khangembam BC; Sharma P; Karunanithi S; Singhal A; Das CJ; Kumar P; Julka PK; Bandopadhyaya GP; Kumar R; Malhotra A; Bal C
Nucl Med Commun; 2013 Nov; 34(11):1046-54. PubMed ID: 24025920
[TBL] [Abstract][Full Text] [Related]
11. Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer.
Cohn DE; Hall NC; Povoski SP; Seamon LG; Farrar WB; Martin EW
Gynecol Oncol; 2008 Aug; 110(2):152-7. PubMed ID: 18539314
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.
Sivesgaard K; Larsen LP; Sørensen M; Kramer S; Schlander S; Amanavicius N; Bharadwaz A; Tønner Nielsen D; Viborg Mortensen F; Morre Pedersen E
Eur Radiol; 2018 Nov; 28(11):4735-4747. PubMed ID: 29736846
[TBL] [Abstract][Full Text] [Related]
14. Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer.
Liao S; Lan X; Cao G; Yuan H; Zhang Y
Clin Nucl Med; 2013 Sep; 38(9):715-20. PubMed ID: 23856825
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
[TBL] [Abstract][Full Text] [Related]
16. PET-CT vs. CT alone in ovarian cancer recurrence.
Sebastian S; Lee SI; Horowitz NS; Scott JA; Fischman AJ; Simeone JF; Fuller AF; Hahn PF
Abdom Imaging; 2008; 33(1):112-8. PubMed ID: 17404789
[TBL] [Abstract][Full Text] [Related]
17. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging/positron emission tomography provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration.
Vargas HA; Burger IA; Donati OF; Andikyan V; Lakhman Y; Goldman DA; Schöder H; Chi DS; Sala E; Hricak H
Int J Gynecol Cancer; 2013 Oct; 23(8):1512-9. PubMed ID: 24257566
[TBL] [Abstract][Full Text] [Related]
19. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
